(Q39212591)

4 March 2018

title

Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma (English)

1 reference

4 March 2018

1 reference

4 March 2018

Susanna V Ulahannan

0 references

Heiner Wedemeyer

1 reference

4 March 2018

David E. Kleiner

object named as

David E Kleiner

1 reference

4 March 2018

author name string

Austin G Duffy

1 reference

4 March 2018

Oxana Makorova-Rusher

1 reference

4 March 2018

Osama Rahma

1 reference

4 March 2018

Drew Pratt

1 reference

4 March 2018

Jeremy L Davis

1 reference

4 March 2018

Marybeth S Hughes

1 reference

4 March 2018

Theo Heller

1 reference

4 March 2018

Mei ElGindi

1 reference

4 March 2018

Ashish Uppala

1 reference

4 March 2018

Firouzeh Korangy

1 reference

4 March 2018

William D Figg

1 reference

4 March 2018

David Venzon

1 reference

4 March 2018

Seth M Steinberg

1 reference

4 March 2018

Aradhana M Venkatesan

1 reference

4 March 2018

Venkatesh Krishnasamy

1 reference

4 March 2018

Nadine Abi-Jaoudeh

1 reference

4 March 2018

Elliot Levy

1 reference

4 March 2018

Tim F Greten

1 reference

4 March 2018

publication date

2 November 2016

1 reference

4 March 2018

published in

Journal of Hepatology

1 reference

4 March 2018

volume

1 reference

4 March 2018

issue

1 reference

4 March 2018

page(s)

545-551

1 reference

4 March 2018

The yin and yang of evasion and immune activation in HCC.

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Hepatocellular carcinoma from an immunologic perspective

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Standardizing immunophenotyping for the Human Immunology Project

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Sorafenib in advanced hepatocellular carcinoma

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5316490

Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine

2 December 2018

1 reference

12 December 2020

Radiofrequency Thermal Ablation for Hepatocellular Carcinoma Stimulates Autologous NK-Cell Response

1 reference

12 December 2020

Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization

1 reference

12 December 2020

Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes

1 reference

12 December 2020

Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma

1 reference

12 December 2020

10.1016/J.JHEP.2016.10.029

Identifiers

DOI

1 reference

4 March 2018

PMC publication ID

5316490

1 reference

4 March 2018

PubMed publication ID

27816492

1 reference

4 March 2018